Accueil   Diary - News   All news Calixar launches new funding round to establish business strategy

Calixar launches new funding round to establish business strategy


Calixar aims to become a leader in early drug discovery segment through
unique technology and pipeline of novel and high-quality therapeutic targets


Funds will enable company to isolate around 100 priority targets for the pharmaceutical industry


Lyon, France, March 9, 2020 – Calixar, a biotechnology company specialized in the isolation of complex therapeutic targets and native antigens, announces today the start of a new funding round of €2.5M ($2.7M). This strategic investment will enable the company to develop a unique pipeline of therapeutic targets and become a key player in the drug development industry. In 2019, the recognized quality of Calixar’s therapeutic targets led the US biotech company Regeneron to enter into an exclusive licensing agreement with Calixar for a major target. This agreement confirmed Calixar's business strategy based on licensing out therapeutic targets and developing a catalog of molecules with an expected value of €92m-€923M ($100M to $1bn).


Since its initial funding round in 2012, Calixar has developed a unique isolation and stabilization technology and built a strong reputation within the pharma field. The company’s turnover in 2019 was around €1.01M ($1.1M), 90% of which was international. This new funding round will allow Calixar to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest. The aim of this fundraising is for Calixar to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth €70bn ($76bn) by 2025 (Statista).



Read the press release